Related references
Note: Only part of the references are listed.KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Sandra Misale et al.
CLINICAL CANCER RESEARCH (2019)
PICKLES: the database of pooled in-vitro CRISPR knockout library essentiality screens
Walter F. Lenoir et al.
NUCLEIC ACIDS RESEARCH (2018)
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Andrew J. Aguirre et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer
Shuai Li et al.
CLINICAL CANCER RESEARCH (2018)
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Marta Roman et al.
MOLECULAR CANCER (2018)
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Dietrich A. Ruess et al.
NATURE MEDICINE (2018)
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
Sara Mainardi et al.
NATURE MEDICINE (2018)
Afatinib restrains K-RAS-driven lung tumorigenesis
Herwig P. Moll et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
The ERBB network facilitates KRAS-driven lung tumorigenesis
Bjorn Kruspig et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers
Robert J. Nichols et al.
NATURE CELL BIOLOGY (2018)
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
Collin M. Blakely et al.
NATURE GENETICS (2017)
Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells
Robin M. Meyers et al.
NATURE GENETICS (2017)
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer
Adrian Vallejo et al.
NATURE COMMUNICATIONS (2017)
Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C
Mei Zeng et al.
CELL CHEMICAL BIOLOGY (2017)
RAS Proteins and Their Regulators in Human Disease
Dhirendra K. Simanshu et al.
CELL (2017)
Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras
Tim Wang et al.
CELL (2017)
BAGEL: a computational framework for identifying essential genes from pooled library screens
Traver Hart et al.
BMC BIOINFORMATICS (2016)
Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
Christopher J. Tape et al.
CELL (2016)
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer
Jimi Kim et al.
NATURE (2016)
Overcoming resistance to HER2 inhibitors through state-specific kinase binding
Chris J. Novotny et al.
NATURE CHEMICAL BIOLOGY (2016)
Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Piro Lito et al.
SCIENCE (2016)
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
Matthew P. Patricelli et al.
CANCER DISCOVERY (2016)
Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation
Max A. Horlbeck et al.
ELIFE (2016)
Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions
Saori Fujita-Sato et al.
CANCER RESEARCH (2015)
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Julian Downward
CLINICAL CANCER RESEARCH (2015)
PhosphoNetworks: a database for human phosphorylation networks
Jianfei Hu et al.
BIOINFORMATICS (2014)
MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments
Meena Choi et al.
BIOINFORMATICS (2014)
Oncogenic KRAS signalling in pancreatic cancer
S. Eser et al.
BRITISH JOURNAL OF CANCER (2014)
The RhoGEF GEF-H1 Is Required for Oncogenic RAS Signaling via KSR-1
Jane Cullis et al.
CANCER CELL (2014)
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
Luke A. Gilbert et al.
CELL (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
RegPhos 2.0: an updated resource to explore protein kinase-substrate phosphorylation networks in mammals
Kai-Yao Huang et al.
DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer
Hyun Seok Kim et al.
CELL (2013)
Identification of Mutant K-Ras-dependent Phenotypes Using a Panel of Isogenic Cell Lines
Steffan Vartanian et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
RNAi screens in mice identify physiological regulators of oncogenic growth
Slobodan Beronja et al.
NATURE (2013)
mTORC1 Status Dictates Tumor Response to Targeted Therapeutics
Ilana Kelsey et al.
SCIENCE SIGNALING (2013)
Systematic Functional Prioritization of Protein Posttranslational Modifications
Pedro Beltrao et al.
CELL (2012)
Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks
Michael J. Lee et al.
CELL (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
Levi A. Garraway et al.
CANCER DISCOVERY (2012)
From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets
Cheryl Eifert et al.
NATURE REVIEWS CANCER (2012)
Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
Noriaki Sunaga et al.
MOLECULAR CANCER THERAPEUTICS (2011)
A mammalian functional-genetic approach to characterizing cancer therapeutics
Hai Jiang et al.
NATURE CHEMICAL BIOLOGY (2011)
A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
Marta Puyol et al.
CANCER CELL (2010)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Ji Luo et al.
CELL (2009)
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Da Wei Huang et al.
NATURE PROTOCOLS (2009)
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Keiran S. M. Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2008)
MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification
Juergen Cox et al.
NATURE BIOTECHNOLOGY (2008)
Establishment of human tumor xenografts in immunodeficient mice
Christopher L. Morton et al.
NATURE PROTOCOLS (2007)
Share Paper
